Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal).
OBJECTIVE: To evaluate the performance of QCancer® (Gastro-Oesophageal) for predicting the risk of undiagnosed gastro-oesophageal cancer in an independent UK cohort of patients from general practice records. DESIGN: Open cohort study to validate QCancer® (Gastro-Oesophageal) prediction model. Three...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1826273194535813120 |
|---|---|
| author | Collins, G Altman, D |
| author_facet | Collins, G Altman, D |
| author_sort | Collins, G |
| collection | OXFORD |
| description | OBJECTIVE: To evaluate the performance of QCancer® (Gastro-Oesophageal) for predicting the risk of undiagnosed gastro-oesophageal cancer in an independent UK cohort of patients from general practice records. DESIGN: Open cohort study to validate QCancer® (Gastro-Oesophageal) prediction model. Three hundred sixty-five practices from the United Kingdom contributing to The Health Improvement Network database. 2.1 million patients registered with a general practice surgery between 01 January 2000 and 30 June 2008, aged 30-84years (3.7 million person years) with 1766 gastro-oesophageal cancer cases. The outcome, gastro-oesophageal cancer was defined as incident diagnosis of gastro-oesophageal cancer during the 2years after study entry. RESULTS: The results from this independent and external validation of QCancer® (Gastro-Oesophageal) demonstrated good performance data on a large cohort of general practice patients. QCancer® (Gastro-Oesophageal) had very good discrimination with c-statistics of 0.93 and 0.94 for women and men respectively. QCancer® (Gastro-Oesophageal) was well calibrated across all tenths of risk and over all age ranges with predicted risks closely matching observed risks. QCancer® (Gastro-Oesophageal) explained 74.4% and 75.6% of the variation in men and women respectively. CONCLUSIONS: QCancer® (Gastro-Oesophageal) is a useful tool to identify undiagnosed gastro-oesophageal cancer in primary care in the United Kingdom. |
| first_indexed | 2024-03-06T22:24:28Z |
| format | Journal article |
| id | oxford-uuid:5630db97-8522-42ad-8ec6-0c8045a2c548 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:24:28Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:5630db97-8522-42ad-8ec6-0c8045a2c5482022-03-26T16:48:48ZIdentifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5630db97-8522-42ad-8ec6-0c8045a2c548EnglishSymplectic Elements at Oxford2013Collins, GAltman, DOBJECTIVE: To evaluate the performance of QCancer® (Gastro-Oesophageal) for predicting the risk of undiagnosed gastro-oesophageal cancer in an independent UK cohort of patients from general practice records. DESIGN: Open cohort study to validate QCancer® (Gastro-Oesophageal) prediction model. Three hundred sixty-five practices from the United Kingdom contributing to The Health Improvement Network database. 2.1 million patients registered with a general practice surgery between 01 January 2000 and 30 June 2008, aged 30-84years (3.7 million person years) with 1766 gastro-oesophageal cancer cases. The outcome, gastro-oesophageal cancer was defined as incident diagnosis of gastro-oesophageal cancer during the 2years after study entry. RESULTS: The results from this independent and external validation of QCancer® (Gastro-Oesophageal) demonstrated good performance data on a large cohort of general practice patients. QCancer® (Gastro-Oesophageal) had very good discrimination with c-statistics of 0.93 and 0.94 for women and men respectively. QCancer® (Gastro-Oesophageal) was well calibrated across all tenths of risk and over all age ranges with predicted risks closely matching observed risks. QCancer® (Gastro-Oesophageal) explained 74.4% and 75.6% of the variation in men and women respectively. CONCLUSIONS: QCancer® (Gastro-Oesophageal) is a useful tool to identify undiagnosed gastro-oesophageal cancer in primary care in the United Kingdom. |
| spellingShingle | Collins, G Altman, D Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal). |
| title | Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal). |
| title_full | Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal). |
| title_fullStr | Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal). |
| title_full_unstemmed | Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal). |
| title_short | Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal). |
| title_sort | identifying patients with undetected gastro oesophageal cancer in primary care external validation of qcancer r gastro oesophageal |
| work_keys_str_mv | AT collinsg identifyingpatientswithundetectedgastrooesophagealcancerinprimarycareexternalvalidationofqcancergastrooesophageal AT altmand identifyingpatientswithundetectedgastrooesophagealcancerinprimarycareexternalvalidationofqcancergastrooesophageal |